THE BODY FILLER

A sensational novelty. A brand new treatment for an immediate rejuvenation. The new-born hyaluronic acid in the RESTYLANE family was recently showed at the last IMCAS international conference of Paris as the world leader among injectable reabsorbable fillers for aesthetic rejuvenation. We talk about it with Dr. Magda Belmontesi, dermatologist: “It’s called MACROLANE and represents a novelty in the world of aesthetics. In fact, until today all reabsorbable fillers had been used only on face. We talk in particular about the RESTYLANE family, characterized by the uniqueness of the NASHA hyaluronic acid (= Not Animal Stabilized Hyaluronic Acid) with a less than 1% modified molecule, therefore the most similar one to our skin’s hyaluronic acid, that represents the world leader in safety, efficacy and scientific validity. In over 80 countries around the world women – and now men, too – choose Restylane for wrinkle correction and face rejuvenation and more than 9,000,000 treatments are made with utmost safety and no side effects.”
How does this new treatment differ? Dr. Belmontesi further explains:
“MACROLANE is a revolutionary product because it is the first and only NASHA hyaluronic acid-based reabsorbable body filler. In this case, we can consider it the first filler for safe, natural and effective body reshaping. In Japan, where eastern women are slender and small-breasted, it is used to give volume (1 or 2 sizes) with a soft and natural effect! Of course, it doesn’t replace big prostheses for breast augmentation but it is absolutely innovative.”
Its use is suggested also for specific problems, isn’t it?
“Yes, it is – Dr. Magda Belmontesi tell us. “MACROLANE is also useful for the correction of possible ”holes” left by liposuction on the buttocks and of the “pectus excavatum”, a quite frequent problem that often causes aesthetic embarrassment, especially to youngsters who feel ashamed of not being able to show a sturdy chest, but rather receding towards the inside.”
Macrolane has been present on the Italian market for a short time and is produced by the swedish biotechnology firm Q-Med.